No Data
No Data
Express News | Palisade Bio Q1 EPS $(4.59) Misses $(4.28) Estimate
Express News | Palisade Bio Inc- Qtrly Shr Loss $ 4.59
Express News | Palisade Bio Inc - Sufficient Cash on Hand to Execute on Business Plan and Reach Clinical and Regulatory Milestones Into 2025
Palisade Bio 1Q Loss/Shr $4.59 >PALI
Palisade Bio 1Q Loss/Shr $4.59 >PALI
Palisade Bio 1Q Research and Development Expenses $2.2M >PALI
Palisade Bio 1Q Research and Development Expenses $2.2M >PALI
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end– Sufficient cash on hand to execute on bu
No Data